Johnson Controls International PLC vs BIO-TECHNE Corp — how do they compare? Johnson Controls International PLC trades at $154.65 (market cap $91.29B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Johnson Controls International PLC is far larger — about 8.1× BIO-TECHNE Corp's market cap, and Johnson Controls International PLC pays the higher dividend (1.06%). Which is the better fit depends on your goals.
| JCI | TECH | |
|---|---|---|
Market Cap | $91.29B | $11.24B |
Sector | Industrials | Health |
52-Week High | $154.55 | $72.29 |
52-Week Low | $103.52 | $43.31 |
Enterprise Value | $100.12B | $11.32B |
Dividend Yield | 1.06% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $152.21, down 1.51% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with EPS of $1.42 versus $1.30 expected, and raised full-year guidance. Fundamentals show solid revenue growth and expanding net income margins, though valuation multiples like a P/E of 42.88 appear elevated. Recent news highlights strong demand for its thermal management systems, particularly in data centers.
JCI's outlook is positive, driven by operational strength and strategic positioning in high-growth markets like AI infrastructure. Investment opportunities include continued earnings beats and market share gains in energy efficiency solutions. Key risks involve high valuation sensitivity, competitive pressures, and macroeconomic factors affecting construction and industrial spending. The consensus price target of $168.25 suggests ~10% upside from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →